A registrational study of Pelareorep in Colorectal cancer
Latest Information Update: 22 Mar 2026
At a glance
- Drugs Pelareorep (Primary)
- Indications Colorectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms REO-033
Most Recent Events
- 22 Mar 2026 New trial record
- 25 Feb 2026 According to an Oncolytics media release, the company plans to launch a controlled study with the first clinical site activating in March and interim data expected by YE-2026.